HTG Receives Phase II SBIR Award to Continue Development of Sequencing Products | GenomeWeb

NEW YORK (GenomeWeb News) – The National Human Genome Research Institute has awarded HTG Molecular Diagnostics a $1.01 million award to continue development of targeted sequencing products, the Tucson, Ariz.-based company said today.

The one-year Phase II Small Business Innovation Research grant allows HTG to continue work that was carried out under a $599,000 Phase I SBIR grant to the company for the Nuclease Robe Mediated Sequencing Project (HTG EdgeSeq), which seeks to develop targeted sequencing products using HTG's core RNA analysis technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

HHS Secretary Tom Price says the NIH budget contains unneeded expenses that can be trimmed, Stat News reports.

The chair of the House science committee says the journal Science is not objective, the Huffington Post reports.

In Nature this week: glioma GWAS uncovers new risk loci, and more.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Apr
13
Sponsored by
SeraCare

In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay. 

Apr
27
Sponsored by
SeraCare

This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.

May
09
Sponsored by
SeraCare

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.